Experienced in Angiosarcoma

Shiyong W. Zhou

Key Laboratory Of Cancer Prevention And Therapy, 
Tianjin, CN 
Experienced in Angiosarcoma
Key Laboratory Of Cancer Prevention And Therapy, 
Tianjin, CN 
OverviewLocationsClinical Research

Overview

Shiyong Zhou practices in Tianjin, China. Zhou is rated as an Experienced expert by MediFind in the treatment of Angiosarcoma. Their top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Follicular Lymphoma.

Their clinical research consists of co-authoring 68 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Angiosarcoma.

Locations

Key Laboratory Of Cancer Prevention And Therapy, Tianjin, China
Other Locations
National Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine, Key Laboratory Of Cancer Prevention And Therapy, Huanhuxi Road, Tiyuanbei, Dayingmen, 300060, China
Beijing, 100871, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 2

68 Total Publications

Correction: Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study.
Correction: Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study.
Journal: Frontiers in immunology
Published: June 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile